Ocular Therapeutix Inc
OCULHealthcare|Biotechnology|USA
$10.21
-0.34 (-3.27%)
Tangible Book
$2.66
Upcoming Data Readouts (3)
Jan 2027
Est. completion
P3Neovascular Age-related Macular Degeneration
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918n=825
Mar 2027
Est. completion
P3Non-Proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
NCT07235085n=930
Aug 2030
Est. completion
P3Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
NCT07516132n=850
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Apr 2026
P3
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
NCT06223958